Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Ltd (OKYO) is a clinical-stage biopharmaceutical company pioneering novel therapies for ocular inflammatory conditions and neuropathic pain. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory developments, and strategic partnerships.
Investors and researchers will find timely updates on OKYO's lead candidate OK-101, a patented chemerin analog targeting dry eye disease and corneal neuropathic pain. All content is sourced directly from company filings and press releases to ensure accuracy.
The news archive includes updates on: Phase 2 clinical trial progress, intellectual property milestones, research collaborations, and regulatory pathway developments. Content is organized chronologically for tracking therapeutic advancement timelines.
Bookmark this page for streamlined access to OKYO's latest scientific and corporate developments. Check regularly for updates on ocular therapeutic innovations with potential to address unmet medical needs in global markets.
FAQ
What is the current stock price of OKYO PHARMA (OKYO)?
What is the market cap of OKYO PHARMA (OKYO)?
